# A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

> **NCT07630714** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 24 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **COMBINATION_PRODUCT:** Anifrolumab + APFS

## Key facts

- **NCT ID:** NCT07630714
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2030-09-02
- **Final completion:** 2031-09-05
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07630714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07630714, "A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07630714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*